Status:
COMPLETED
Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)
Lead Sponsor:
Actelion
Conditions:
Clostridium Difficile Infection
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Cadazolid is a new antibiotic developed for the treatment of Clostridiun difficile associated diarrhea (CDAD), also known as Clostridium Difficile Infection (CDI). The purpose of the study was to eval...
Eligibility Criteria
Inclusion
- Key
- Male or female
- At least 18 years of age
- With a diagnosis of Clostridium Difficile-associated diarrhea (CDAD): first occurrence or first recurrence.
- Key
Exclusion
- Concurrent life threatening condition.
- Immuno-compromised subjects, concomittant immuno-suppresive treatment.
- Concomitant antimicrobial treatment for CDAD.
- Any circumstances or conditions, which, in the opinion of the investigator, would affect full participation of the subject in the study or compliance with the protocol
Key Trial Info
Start Date :
January 25 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 12 2012
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT01222702
Start Date
January 25 2011
End Date
November 12 2012
Last Update
June 14 2017
Active Locations (23)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Investigative Site 6902
Newark, Delaware, United States, 19718
2
Clinical Investigative Site 6919
Jacksonville, Florida, United States, 32207
3
Clinical Investigative Site 6938
Orlando, Florida, United States, 32837
4
Clinical Investigative Site 6930
Decatur, Georgia, United States, 30033